BioBridgeX
Log inCompare quotes
Preclinical / Nonclinical

In Vitro Pharmacology CROs

Free for buyersNeutral marketplace
Quick answer

In vitro pharmacology is the bench testing that confirms your drug candidate hits its intended target, and only that target, in biochemical and cell-based assays. You source it in preclinical development before committing to in vivo work. On BioBridgeX, buyers compare qualified in vitro pharmacology CROs and contract under one agreement, free for buyers.

In Vitro Pharmacology CROs on BioBridgeX

We are qualifying and publishing In Vitro Pharmacology CROs now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is in vitro pharmacology and when do you need it?

In vitro pharmacology is the bench work that proves your molecule does what you think it does, at the level of a purified protein or a living cell, before any animal is dosed. It answers the most basic questions a program has to clear: does the compound bind or modulate its intended target, how potent is it, is it selective, and does it trip any obvious off-target liability that would sink the program later. The work is done in a dish (in vitro, literally "in glass"), which is exactly why it is fast and cheap relative to everything downstream.

You reach for this work right after discovery hands you a lead or a short series. Discovery may have screened thousands of compounds; in vitro pharmacology is where you characterize the few survivors properly, with clean dose-response and orthogonal confirmation, so you can rank them and pick what to carry into in vivo efficacy and DMPK. It is also where you generate the target-engagement and selectivity data a later IND package leans on, and where cardiac and other safety flags first surface. Catching a hERG problem in a patch-clamp assay is a great deal cheaper than discovering it in a tox study.

Almost all of this is non-GLP, decision-grade science. Its purpose is to inform your go/no-go calls, not to satisfy a regulator, so it runs under good scientific practice with qualified assays and traceable data rather than full GLP. That distinction is what keeps the budget sane: you fail weak candidates here, on inexpensive assays, before you commit to the expensive studies that follow. The assay menu does shift by modality. A small molecule leans on enzyme and receptor assays and a hERG read; an antibody leans on binding affinity (SPR or BLI), cell-based functional potency, and FcgR or complement panels.

What does an in vitro pharmacology CRO actually do?

A good in vitro pharmacology CRO is, in practice, an assay shop with deep pharmacology judgment. They build or already run the readout that reports your compound's activity, qualify it so the numbers are reproducible, then generate the binding, potency, selectivity, and liability data you use to choose a candidate. The specific assays depend on your target class and modality, but the core menu is consistent across suppliers.

  • Target engagement and potency: biochemical (enzyme, kinase, GPCR) and cell-based assays with full dose-response, reporting IC50, EC50, Ki, or Kd so you can rank compounds on real potency, not single-point activity.
  • Binding kinetics and affinity: SPR (Biacore), BLI (Octet), or radioligand binding to measure on/off rates and affinity, which matters most for biologics and for residence-time-driven programs.
  • Functional assays: agonist, antagonist, or inverse-agonist characterization, second-messenger readouts (cAMP, calcium flux, beta-arrestin), and reporter-gene systems that show the compound's actual functional effect, not just that it binds.
  • Selectivity and off-target screening: counter-screens against related family members (a kinase panel, a GPCR panel) and broad safety-pharmacology profiling (such as a CEREP-style panel) to catch promiscuity before it becomes a clinical surprise.
  • Cardiac and ion-channel liability: hERG by manual or automated patch-clamp, plus other cardiac ion channels (Nav1.5, Cav1.2) and a CiPA-aligned panel where pro-arrhythmia risk is a real concern.
  • Mechanism-of-action and cellular readouts: proliferation, viability, apoptosis, reporter assays, and target-engagement assays (CETSA, NanoBRET) that connect binding to a cellular consequence.

How do you choose an in vitro pharmacology CRO?

Start with fit to your target class and modality, not the size of the logo. A lab that runs flawless kinase enzyme assays may have never touched a GPCR functional panel or an antibody potency assay, and the right assay format for an ion channel is nothing like the right format for a nuclear receptor. The supplier whose existing, validated assay already detects your compound at the concentration you care about is worth more than a bigger shop spinning the assay up for the first time on your budget.

The other thing that separates a clean engagement from a frustrating one is how they report. You want the raw curves, the fit parameters, the assay acceptance criteria (Z-prime, signal window), and honest flagging of compounds that misbehaved, not just a tidy IC50 table. Confirm turnaround on the panel and not only the bench time, since a fast assay with a slow report still stalls your decision. Use the checklist below to compare two or three suppliers against the same written scope.

  • Quality and GxP status: most in vitro pharmacology is non-GLP and decision-grade, so confirm whether you actually need GLP for a given assay (you usually do not) and avoid paying GLP premiums for exploratory work. Ask about assay qualification, SOPs, and data-integrity practices.
  • Assay and target-class fit: confirm the specific assay (your exact target, receptor subtype, or ion channel) is already validated and running in-house, ideally with reference compounds and historical control data, not built fresh for your project.
  • Modality fit: match the menu to small molecule, antibody, peptide, oligonucleotide, ADC, or cell and gene therapy, since binding (SPR/BLI), functional potency, and selectivity formats differ completely across these.
  • Capacity and lead time: ask about the current queue and realistic report turnaround, not just bench time. A great lab booked solid for months can be slower than a good lab with an open slot.
  • Sensitivity and range: confirm the assay's dynamic range and detection limit cover the potency you expect, so a sub-nanomolar compound is not flattened against an assay floor.
  • Data quality and reporting: insist on raw dose-response curves, fit parameters, acceptance criteria (Z-prime, signal-to-background), and clear flagging of failed or anomalous wells.
  • Region and regulatory track record: if any data will feed an IND, confirm the supplier can run the relevant assay to GLP when needed and has supported submissions in your target region.
  • IP and confidentiality: settle who owns the data and any assay-derived findings, and confirm a CDA is in place before you disclose a sensitive target or compound structure.

Frequently asked questions

What is the difference between in vitro and in vivo pharmacology?
In vitro pharmacology tests your compound in a dish, against a purified target or in cultured cells: binding, dose-response (IC50/EC50), functional readouts, and selectivity. In vivo pharmacology tests it in a living animal to show efficacy in a disease-relevant model. In vitro tells you whether the mechanism works and how potent and selective the compound is; in vivo tells you whether that translates into a real effect at a tolerable exposure. You almost always run in vitro first, because it is faster and cheaper and it tells you which compounds are even worth dosing in an animal.
What assays are included in an in vitro pharmacology package?
It depends on your target and modality, but a typical package covers target engagement and potency (enzyme, receptor, or cell-based assays with full dose-response giving IC50, EC50, Ki, or Kd), binding affinity and kinetics (SPR or BLI), functional characterization (agonist/antagonist, cAMP, calcium flux, reporter assays), selectivity counter-screens against related targets, and cardiac liability work such as a hERG patch-clamp. Define the exact assays and target subtypes in your scope so you can compare supplier quotes on the same specification rather than a generic price.
Do in vitro pharmacology studies need to be GLP compliant?
Usually not. Most in vitro pharmacology is exploratory, decision-grade work that informs which candidate you advance, so it runs under good scientific practice with qualified, reproducible assays rather than full GLP. GLP applies to the pivotal safety studies in the IND-enabling stage. The exception is when a specific result, for example a definitive hERG assessment, is intended to support your regulatory package, in which case you would run that particular assay to GLP. Know which bucket each assay sits in before you sign the scope, so you neither overpay for GLP you do not need nor assume exploratory data will satisfy a reviewer.
How much do in vitro pharmacology assays cost and how long do they take?
Per-assay, in vitro pharmacology is among the cheapest preclinical work, which is exactly why you run it early to retire weak candidates. Cost scales with the number of compounds, the assay format (a simple biochemical assay is cheaper than a complex cell-based functional or patch-clamp panel), and how much selectivity and counter-screening you add. Turnaround for a defined panel is often a few weeks rather than months, though a custom assay that has to be developed and qualified first takes longer. Any supplier quoting a flat number before seeing your target and compound list is guessing; get itemized quotes against one written scope.
What is a hERG assay and why does it matter at this stage?
The hERG assay measures whether your compound blocks the hERG potassium channel, which is the main early flag for QT prolongation and cardiac arrhythmia risk. It is run by manual or automated patch-clamp and is one of the most common in vitro safety reads in early pharmacology. Catching a hERG liability now, on an inexpensive in vitro assay, is far cheaper than discovering it later in a tox study or, worse, in the clinic. For programs where pro-arrhythmia risk is a real concern, suppliers can extend this to other cardiac ion channels and a CiPA-aligned panel.
Is sourcing in vitro pharmacology CROs on BioBridgeX free for buyers?
Yes. BioBridgeX is free for buyers and acts as the neutral marketplace with no lab of its own, so there is no incentive to steer your assays toward a preferred site. Suppliers pay a flat 2% platform fee, the same rate on a small selectivity panel or a multi-assay pharmacology package. You describe the target, modality, and assays you need, compare qualified in vitro pharmacology CROs on capability and transparent quotes, and contract once. When you split work across suppliers, you compare quotes and contract directly with each chosen supplier, in one place.

Source In Vitro Pharmacology with one contract

Compare transparent quotes from qualified In Vitro Pharmacology CROs, then contract once. Free for buyers.

Compare quotes